93353-67-4 Usage
Uses
Used in Pharmaceutical Industry:
7-bromo-1-naphthoic acid methyl ester is used as a synthetic intermediate for the development of new drugs. Its unique structure and reactivity allow for the creation of a variety of pharmaceutical compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 7-bromo-1-naphthoic acid methyl ester is utilized as a precursor in the synthesis of various agrochemicals. Its chemical properties make it suitable for the development of compounds with pesticidal or herbicidal properties, contributing to enhanced crop protection.
Used in Materials Science:
7-bromo-1-naphthoic acid methyl ester is employed as a building block in the preparation of advanced materials. Its incorporation into material structures can lead to the development of new properties, such as improved stability, enhanced functionality, or specific interactions with other molecules, making it a valuable component in material science research and development.
Used in Organic Synthesis:
As a key intermediate in organic synthesis, 7-bromo-1-naphthoic acid methyl ester is used for the preparation of a wide range of organic compounds. Its versatility in reactions allows chemists to explore new synthetic routes and create novel molecules with diverse applications across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 93353-67-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,3,5 and 3 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 93353-67:
(7*9)+(6*3)+(5*3)+(4*5)+(3*3)+(2*6)+(1*7)=144
144 % 10 = 4
So 93353-67-4 is a valid CAS Registry Number.
93353-67-4Relevant academic research and scientific papers
PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
-
Paragraph 0714; 0715, (2021/03/19)
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase
Giardina, Sarah F.,Werner, Douglas S.,Pingle, Maneesh,Feinberg, Philip B.,Foreman, Kenneth W.,Bergstrom, Donald E.,Arnold, Lee D.,Barany, Francis
, p. 3004 - 3027 (2020/04/17)
β-Tryptase, a homotetrameric serine protease, has four identical active sites facing a central pore, presenting an optimized setting for the rational design of bivalent inhibitors that bridge two adjacent sites. Using diol, hydroxymethyl phenols or benzoyl methyl hydroxamates, and boronic acid chemistries to reversibly join two [3-(1-acylpiperidin-4-yl)phenyl]methanamine core ligands, we have successfully produced a series of self-assembling heterodimeric inhibitors. These heterodimeric tryptase inhibitors demonstrate superior activity compared to monomeric modes of inhibition. X-ray crystallography validated the dimeric mechanism of inhibition, and compounds demonstrated high selectivity against related proteases, good target engagement, and tryptase inhibition in HMC1 xenograft models. Screening 3872 possible combinations from 44 boronic acid and 88 diol derivatives revealed several combinations that produced nanomolar inhibition, and seven unique pairs produced greater than 100-fold improvement in potency over monomeric inhibition. These heterodimeric tryptase inhibitors demonstrate the power of target-driven combinatorial chemistry to deliver bivalent drugs in a small molecule form.
